Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

COVID-19 vaccination for hematopoietic stem cell transplant patients

The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular,...

How can we use microbial-derived metabolites to prevent GvHD?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Erik Thiele...

FDA approval of ruxolitinib for the treatment of patients with chronic GvHD

On September 22, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of ruxolitinib for...

An overview of the role of ATG in preventing acute and chronic GvHD after allo-HSCT

Graft-versus-host disease (GvHD) can significantly impact the morbidity, mortality, and quality of life (QoL) of...

The incidence and clinical characteristics of liver cGvHD onset during calcineurin inhibitor tapering

Chronic graft-versus-host disease (cGvHD) remains a prominent issue in patients with hematologic...

Developments in GvHD prophylaxis in allogenic stem cell transplantation including the role of PTCy

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for...

What is the mechanism of action of the GLP-2 analog, teduglutide, for GvHD treatment?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub...

Updated results from REACH2: Ruxolitinib for steroid-refractory acute GvHD

As previously reported on the GvHD Hub, the initial data from the phase III REACH2 trial uncovered the potential benefit of...

REACH2 study: What is the risk of losing response to ruxolitinib over time?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub...

Phase II HERACLES trial meets its primary objective

On March 17, 2021, it was announced that the phase II HERACLES trial (NCT03359980), evaluating MaaT013 in patients with acute graft-versus-host...